IMMP Immutep LTD ADR

$IMMP Marc, sell the company and let a better resourced player take it forward. Time is your biggest enemy. Don’t wait for the perfect moment, the longer you delay, the more the market will punish you. End your tenure with a sale that delivers value to shareholders and leaves a meaningful legacy on your resume.

$IMMP up 15% Immutep shares are trading higher after the company announced data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody. $IMMP $SPY $XBI

$IMMP Merck is the most logical strategic buyer based on the length of the efti + Keytruda collab. The remaining pipeline is effectively priced at a negative value creating a valuation gap relative to the residual assets in PD L1 negative HNSCC and neoadjuvant STS plus the existing relationship with Merck. IMO, a $500M equity value is achievable where manufacturing questions are resolved and Phase II pathways are clarified. It would represent a material premium.

$IMMP Data from the Phase I single-ascending dose (SAD) study in healthy volunteers demonstrated that a single infusion of IMP761 produced statistically significant, exposure-dependent inhibition of local T-cell-driven immune responses. The multiple ascending dose (MAD) portion of the trial is currently ongoing, with no new safety signals reported to date. Results from the MAD stage are anticipated in the first half of calendar year 2027

$IMMP IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses "Statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers, with greater pharmacodynamic effects at higher IMP761 exposure"

$IMMP 🏥 Immutep announced positive Phase I data for IMP761, its first-in-class LAG-3 agonist antibody, showing statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers and tolerability across seven dose levels, with pharmacokinetics supporting a four-week dosing interval. Timely market event

$IMMP has positive Phase I data showing exposure-dependent inhibition of T-cell responses in a late-breaking ACR abstract.

$IMMP The liquidity is thin enough that exiting my position would dump the price hard. It’s tempting to double down instead, watching how it plays out.

$IMMP nahhh if they just had manufactoring issues than they should reintroduce a phase 3 lung cancer trial. If the drug is working but was not produced properly for the study than they should redo it ofc. Otherwise I believe the drug is not working. GL!